These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 19855434)

  • 21. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
    Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
    BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
    Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
    J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway.
    Zeng J; He SL; Li LJ; Wang C
    Mol Med; 2021 Oct; 27(1):130. PubMed ID: 34666670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
    Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
    Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
    Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
    Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
    Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
    Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
    Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
    Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
    J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.